ARCHIVES

Docetaxel As Adjuvant Therapy Shows Benefit Over Standard

This article is from The Cancer Letter archive.

Vol. 25 No. 6 | June 28, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: House Appropriations Bill Marked Up, Lid Clamped On; Wells Named DCT Board Chairman

July 6, 1984

NIH Director Varmus Names President of Sloan-Kettering, Succeeding Mark

October 15, 1999

GAO Calls For Stronger FDA Enforcement Of Accelerated Approval Followup Studies

October 30, 2009

Herceptin Regimen Minus Adriamycin Increases Survival With Less Toxicity

October 28, 2011

Non-Profit Spent $1.3 Million On Consultants.

March 28, 2008

In Brief: ACS Awards Professorship To Bernstein; HCFA Clears Dana-Farber For Medicare

August 11, 1995